Next up: Russell Dahl ’97, the CEO and founder of Neurodon Corp., received about $3 million in continued funding from the National Institute on Aging of the National Institutes of Health.
The grant will be used to support the completion of key studies of the company’s small molecule therapeutics for Alzheimer’s disease in order to submit to the FDA and begin clinical trials. Neurodon’s small molecules demonstrate the ability to protect neurons and improve learning and memory.